FDA approves lumateperone and deep TMS for major depressive disorder, suggesting new treatment options for patients.
The U.S. Food and Drug Administration (FDA) has recently announced two significant advances in the treatment of major depressive disorder (MDD), a condition affecting millions of adults nationwide. These developments expand therapeutic options for patients who continue to struggle despite standard antidepressant therapy.
No takes yet. Share an insight, caveat, or question.
Valerie A. Canady (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: